<qa>  What is the ratio between Treatment Arm and Control Arm?The objective of the study is to evaluate the superiority of treatment with PegIntron and Rebetol over no antiviral therapy control group in subjects with chronic hepatitis C and type C compensated cirrhosis. Subjects will be randomized in a ratio of 2:1 Treatment Arm to Control Arm. Subjects in the Treatment Arm will receive combination therapy with PegIntron and Rebetol for 48 weeks; then will enter a 24-week post-treatment Follow-up. Subjects who have detectable Hepatitis C Virus-RNA at Treatment Week 24 will discontinue treatment and enter Follow-up. 